• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • Drug Policy and Law
  • Harm Reduction
  • Activism

Drugreporter

News and Films from the Frontline of the War on Drugs

  • News
  • Café
  • Videos
  • About Us
  • EN
    • HU
    • RU

Dose of Science: Is MDMA Neurotoxic for Human Users?

February 8, 2016 | Author: Balázs Szigeti

Tweet

MDMA’s neurotoxicity is the topic of this and many future editions of Dose of Science. The question is not whether MDMA is neurotoxic in an absolute sense, but rather, what is the extent of the damage at various dosing regimens. Stephen Kish’s study [1] from 2010 aims to clarify the picture by employing a range of neuroimaging techniques and cognitive tests on a large sample while controlling for many potential confounding factors. 

The control (n=50) and the ecstasy group (n=49) was matched with respect to age, gender composition and race. There were, however, statistically significant differences between the groups: ecstasy users spent less years in education, had a lower estimated premorbid IQ and had a marked increase in alcohol consumption (3.1±0.4, as against the control group's 1.4±0.3 drinks/week). Another difference, of course, was the history of ecstasy use. Members of the ecstasy group had a mean of 45 days' abstinence from the drug. Users had a monthly mean dose of 5.3 ±1.3 pills (2.2 ± 0.3 pills/use and 2.2 ± 0.3 use/month), although the distribution was skewed as the median is only 2.3 pills/month.

MDMA is the active ingredient of “classic” ecstasy pills. Ecstasy, however, may or may not contain MDMA, along with other psychoactive ingredients. With the rise of new psychoactive substances since the early 2000s, pills have become more adulterated. As a consequence, not even users know what drug is in their pill, and this uncertainty makes it more difficult to interpret studies of ecstasy users. To overcome this problem, Kish’s team have used hair testing to analytically confirm that subjects in the ecstasy group consumed MDMA (hair analysis also provided information about a range of other drugs).

MDMA has been shown to induce serotonergic neurotoxicity in a range of rodent and primate species (serotonergic neurotoxicity means damage to the neurons that produce serotonin). Serotonin is one of the major neurotransmitters in the brain. It is a chemical that is released in between neurons to transmit the electrical signal between them. There are many other neurotransmitters, dopamine for example, but MDMA seems to specifically damage serotonergic neurons. In animal studies, various post-mortem (after death) methods can be used to assess MDMA-induced neurotoxicity , but these techniques are not viable for human studies.

In humans, the binding potential of serotonin transporters (SERT) can be measured as a proxy for the condition of the serotonin system. The advantage is that SERT binding potential can be measured using the non-invasive technique of positron emission tomography (PET) imaging. SERT is a protein which is responsible for bringing back serotonin from the intercellular space within the cell body where it is recycled. If there is often an excess amount of serotonin available, the brain adjusts its own biochemistry by decreasing the number of serotonin transporters, resulting in lower SERT binding potential. Hence decreased SERT binding potential indicates a damaged serotonin system.

PET scans revealed a significant decrease, among ecstasy users, in SERT binding potential in the cerebral cortex  and the hippocampus; no differences, however, were found in the midbrain, thalamus and other sub-cortical areas.  These results suggests that the ecstasy-induced damage is highly specific to articular areas of the brain. A stepwise linear regression model was used to assess which demographic and drug history-related variables could predict the changes in SERT binding potential. The decrease in SERT was related to the total time of ecstasy use and maximum dosage, but it was not related to gender, psychiatric status, structural brain changes, hormonal levels or genetic background. 32 subjects in the ecstasy group co-used methamphetamine, which has also been shown to decrease SERT levels. The pattern of lower SERT levels was similar in the two subgroups (ecstasy users who also used methamphetamine versus ecstasy users who did not use methamphetamine), indicating that the totality of the SERT decrease could not be explained by methamphetamine use in the sample.

To further evaluate possible MDMA-induced changes in the brain, magnetic resonance imaging (MRI) was used to assess brain volume changes. There was no significant association between reduced brain size and ecstasy use. There was, however, a significant reduction in grey matter (grey matter is composed of the cell bodies of neurons), among users who also consumed  methamphetamine. The use of other drugs (cannabis, cocaine) was not associated with volumetric changes.

Ecstasy users typically had lower SERT binding potential, but most of them fell within the range of the control group. The question therefore presents itself, whether there are any functional differences between the groups? To assess this possibility, a range of cognitive tests were conducted in the domains of memory and executive function. In general, ecstasy users performed worse, but  “the magnitude of the mean test score differences was modest and the variance and distribution of scores showed a near total between-group overlap”. The normal or close to normal cognitive performance is consistent with other studies. The differences in cognitive tests persisted even after allowing for IQ and and years spent in education, although the authors suggest that “[users] may have drifted to a poor performance peer group because of inherent premorbid cognitive issues” (subjects in the ecstasy group also had a lower estimated premorbid IQ).

Another concern is that the decreased SERT binding might cause psychiatric disorders, as serotonin has often been linked to mood and perception. 12 subjects in the ecstasy group had some depressive and anxiety-related symptomatology. SERT binding among these 12 users, however, was not significantly different from ecstasy users without a psychiatric problem; hence the study found no evidence to link  low SERT binding potential to mood disorders.

So what was learned from the paper and what further research does it suggest? The study shows that ecstasy users have lower SERT binding potential, which indicates damage to the serotonin system. The extent of the damage was related to the total time of use and maximum dose. The ecstasy group also showed somewhat poorer performance on cognitive tests, but lower SERT could not be linked to mood disorders.

MDMA decreases SERT binding potential, but it is likely that the study overestimates the effect. 65% of the ecstasy group co-used methamphetamine, which itself decreases SERT. SERT binding averaged across all brain regions is -9.5% among subjects who only used ecstasy (n=17), but it is -18% for those who co-used methamphetamine (n=32). Similarly, some cognitive impairment within the ecstasy group could be explained by co-use of methamphetamine (which is known to cause cognitive deficits [2]). To improve our understanding of MDMA-induced serotonin damage and cognitive impairment, future studies should exclude subjects from the ecstasy group who also used methamphetamine.

Finally we note that the study aims to characterise “low and moderate ecstasy users”, but it is questionable whether a mean of  5.3 ±1.3 pills/month is really characteristic of low profile users. In comparison the “grandmother of MDMA”, Ann Shulgin, has suggested that the substance should not be used more than four times a year [3]. In this lower dosage regimen damage is likely to be proportionately smaller.

Balazs Szigeti

References:

[1]: Kish, Stephen J., et al. "Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[11C] DASB and structural brain imaging study." Brain 133.6 (2010): 1779-1797.

[2]: Simon, Sara L., et al. "Cognitive impairment in individuals currently using methamphetamine." The American Journal on Addictions 9.3 (2000): 222-231.

[3]:https://www.erowid.org/culture/characters/shulgin_alexander/shulgin_alexander_interview2.shtml (accessed on Oct 25 2015)

 

Filed Under: Articles Topics: Dose of Science, Drug Policy and Law

Access to this article is free - but to produce articles and videos is not. Drugreporter is a non-profit website that needs your support to provide you with high quality contents.

Become a supporter and make a donation of 5 $ today!

Related articles:

LIFE UNDER OCCUPATION – Part II. Under the power of the Dementors

March 27, 2023 - Igor Kuzmenko

LIFE UNDER OCCUPATION – Part I. The day that changed our lives

March 20, 2023 - Igor Kuzmenko

A World Tired of Drug Prohibition: Impressions at the UN Commission on Narcotic Drugs

March 16, 2023 - Péter Sárosi

Related videos:

Support Igor Kuzmenko – a Ukrainian Video Reporter Documenting Harm Reduction during the War!

March 20, 2023 - István Gábor Takács

Fixpunkt Berlin: Supporting People Who Use Drugs in Berlin 

March 8, 2023 - Péter Sárosi

HR23 Film Festival in Melbourne – Call for Submissions!

March 3, 2023 - István Gábor Takács

You can browse our topics here:

Activism COVID-19 Criminalisation Dose of Science Drug Consumption Rooms Drug Policy and Law European Drug Policy Harm Reduction Hepatitis HIV/AIDS Marijuana Policies Medical Marijuana Needle and syringe programs New Psychoactive Substances Opiate Substitution Overdose Prevention Psychedelic Medicines Regulation and Control Russian Drug Policy Sex Work United Nations Drug Policy US Drug Policy

Primary Sidebar

BECOME A SUPPORTER OF DRUGREPORTER! INVEST THE PRICE OF A COFFEE MONTHLY AND MAKE SURE DRUGREPORTER KEEPS RUNNING!

Subscribe to the Newsletter!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
  • Facebook
  • Twitter
  • YouTube

Search

Drugreporter Video Database

Hundreds of videos on drug policy, harm reduction and human rights for streaming and download, also on a world map!

DRUGREPORTER NEWS

Monthly drug policy news from around the world

Drugreporter café

In our new online video show, we regularly discuss new developments in the world of drug policy with professionals, activists and decision makers. You can also listen to the Drugreporter Café in Podcast format on Spotify or Apple Podcasts!

COVID-19 Harm Reduction Update

On this info page Drugreporter provides regular updates about resources and news on how harm reduction service providers respond to the COVID-19 Epidemic.

Drugreporter Video Advocacy Network

Browse videos produced by members of our Drugreporter Video Advocacy Network, from all around the world!

DRUG USERS NEWS

Russian language videos on drug policy, harm reduction and human rights.

Our award winning animated documentary movie is based on the original audio recording of Kostya Proletarsky, a drug user and HIV activist who died as a result of mistreatment and torture at a Russian prison. Festival appearances, news and resources are available here!

Footer

Rights Reporter Foundation
Hungary, 1032 Budapest
San Marco Street 70.
Email: rightsreporter@rightsreporter.net

Search

Our other websites:

The Rights Reporter Foundation

The Autocracy Analyst

Room for Change Campaign

Room in the 8th District Campaign

A Day in the Life movie website

Drugreporter